These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1250 related articles for article (PubMed ID: 36423150)

  • 21. The way of SARS-CoV-2 vaccine development: success and challenges.
    Dong Y; Dai T; Wang B; Zhang L; Zeng LH; Huang J; Yan H; Zhang L; Zhou F
    Signal Transduct Target Ther; 2021 Nov; 6(1):387. PubMed ID: 34753918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population.
    Bednarski E; Del Rio Estrada PM; DaSilva J; Boukadida C; Zhang F; Luna-Villalobos YA; Rodríguez-Rangel X; Pitén-Isidro E; Luna-García E; Díaz Rivera D; López-Sánchez DM; Tapia-Trejo D; Soto-Nava M; Astorga-Castañeda M; Martínez-Moreno JO; Urbina-Granados GS; Jiménez-Jacinto JA; Serna Alvarado FJ; Enriquez-López YE; López-Arellano O; Reyes-Teran G; Bieniasz PD; Avila-Rios S; Hatziioannou T
    mBio; 2022 Aug; 13(4):e0084022. PubMed ID: 35735743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A perspective on SARS-CoV-2 virus-like particles vaccines.
    Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
    Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants.
    Noor R; Shareen S; Billah M
    Bull Natl Res Cent; 2022; 46(1):96. PubMed ID: 35431535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.
    González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W
    Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.
    Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C
    J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants.
    Liao G; Lau H; Liu Z; Li C; Xu Z; Qi X; Zhang Y; Feng Q; Li R; Deng X; Li Y; Zhu Q; Zhu S; Zhou H; Pan H; Fan X; Li Y; Li D; Chen L; Ke B; Cong Z; Lv Q; Liu J; Liang D; Li A; Hong W; Bao L; Zhou F; Gao H; Liang S; Huang B; Wu M; Qin C; Ke C; Liu L
    Virol J; 2022 Dec; 19(1):212. PubMed ID: 36494863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?
    Pons S; Uhel F; Frapy E; Sérémé Y; Zafrani L; Aschard H; Skurnik D
    Stem Cell Rev Rep; 2023 Apr; 19(3):585-600. PubMed ID: 36422774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence.
    Tatsi EB; Filippatos F; Michos A
    Epidemiol Infect; 2021 Nov; 149():e237. PubMed ID: 34732275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein.
    Lim H; Kim SE; Lee YH; Hwang YH; Kim SH; Kim MY; Chung GT; Kim YJ; Kim D; Lee JA
    Virology; 2022 Aug; 573():118-123. PubMed ID: 35751974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate.
    Mei S; Fan Z; Liu X; Zhao F; Huang Y; Wei L; Hu Y; Xie Y; Wang L; Ai B; Liang C; Xu F; Guo F
    Front Immunol; 2022; 13():911164. PubMed ID: 35935962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea.
    Nham E; Ko JH; Song KH; Choi JY; Kim ES; Kim HJ; Kim B; Lim HY; Kim KC; Jang HC; Lee KH; Song YG; Baek YJ; Ahn JY; Choi JY; Kim YC; Park YS; Choi WS; Bae S; Kim SH; Kang ES; Jeong HW; Kim SW; Kwon KT; Kim SS; Peck KR
    Front Immunol; 2022; 13():968105. PubMed ID: 36211416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 Variants of Concern.
    Choi JY; Smith DM
    Yonsei Med J; 2021 Nov; 62(11):961-968. PubMed ID: 34672129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.